Physician profile
Charis Durham
NPI 1538547401
$6,704.51
in general payments reported to CMS, 2019-2025
66 companies · $1,319 in 2025
The $1,319 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $406 · 2020: $495 · 2021: $845 · 2022: $864 · 2023: $1,238 · 2024: $1,537 · 2025: $1,319.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,764 · Long Term Medical Supply Or Device Loan: $199 · Education: $132.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,763.63 |
| Long Term Medical Supply Or Device Loan | $199.40 |
| Education | $131.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $664.19 | 2019-2025 | Tecvayli, Erleada, Akeega |
| Incyte Corporation | $633.09 | 2020-2025 | Jakafi, Monjuvi, Monjuvi |
| Astrazeneca Pharmaceuticals LP | $471.36 | 2019-2025 | Tagrisso, Enhertu, Calquence |
| Novartis Pharmaceuticals Corporation | $449.81 | 2022-2025 | |
| Lilly USA, LLC | $303.16 | 2022-2025 | Jaypirca, Verzenio, Retevmo |
| Astellas Pharma US INC | $240.51 | 2022-2025 | Padcev, Xtandi, Xospata |
| Pfizer INC. | $215.74 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $214.61 | 2019-2024 | Keytruda, Welireg, Lynparza |
| Kite Pharma, INC. | $153.67 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $142.79 | 2023-2025 | Opdivo |
| Takeda Pharmaceuticals U.S.A., INC. | $134.72 | 2020-2024 | Iclusig, Fruzaqla, Alunbrig |
| Abbvie INC. | $129.32 | 2025 | |
| Genentech USA, INC. | $112.77 | 2021-2025 | Polivy, Columvi, Gazyva |
| Celgene Corporation | $112.02 | 2023-2025 | Reblozyl, Opdivo, Opdualag |
| Intuitive Surgical, INC. | $111.33 | 2024 |
Show all 66 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celltrion USA INC. | $100.39 | 2023-2024 | Vegzelma |
| Exelixis INC. | $93.79 | 2024 | Cabometyx |
| Rigel Pharmaceuticals, INC. | $93.74 | 2020-2023 | Tavalisse, Rezlidhia |
| Amgen INC. | $93.18 | 2019-2022 | |
| Glaxosmithkline, LLC. | $89.83 | 2022-2025 | Ojjaara, Blenrep |
| Dova Pharmaceuticals | $87.92 | 2021 | |
| Amneal Pharmaceuticals LLC | $87.39 | 2024-2025 | Alymsys |
| Pharmacyclics LLC, An Abbvie Company | $86.55 | 2020-2023 | Epkinly |
| Stemline Therapeutics INC. | $86.41 | 2023-2025 | Orserdu |
| Tempus Ai, INC | $84.95 | 2024 | Xt Cdx |
| Jazz Pharmaceuticals INC. | $81.80 | 2024-2025 | |
| Dendreon Pharmaceuticals LLC | $78.89 | 2023-2025 | Provenge |
| Blueprint Medicines Corporation | $76.16 | 2021-2022 | |
| Epizyme, INC. | $72.57 | 2020-2021 | |
| Daiichi Sankyo INC. | $69.18 | 2023-2025 | Enhertu, Injectafer |
| Regeneron Healthcare Solutions, INC. | $68.92 | 2021-2022 | |
| Taiho Oncology, INC. | $66.14 | 2021-2023 | |
| Karyopharm Therapeutics INC. | $64.65 | 2021-2023 | Xpovio |
| Puma Biotechnology, INC. | $62.28 | 2023-2025 | |
| Array Biopharma INC | $62.17 | 2023-2025 | Lorbrena, Mektovi, Braftovi |
| Seagen INC. | $60.23 | 2021-2023 | Tukysa |
| Acrotech Biopharma INC. | $59.90 | 2021-2022 | |
| Clovis Oncology, INC. | $55.00 | 2019 | |
| Octapharma USA, INC. | $53.26 | 2023 | Octagam Immune Globulin (Human) |
| Adaptive Biotechnologies Corporation | $51.94 | 2020 | |
| Sobi, INC | $47.62 | 2024-2025 | |
| Novocure INC. | $47.61 | 2021-2025 | Optune Lua (Novottf-200t) |
| Mirati Therapeutics, INC. | $41.29 | 2023-2024 | Krazati |
| Morphosys, US INC. | $40.40 | 2022-2023 | Monjuvi |
| Ipsen Biopharmaceuticals, INC | $39.63 | 2022-2024 | Onivyde |
| Servier Pharmaceuticals LLC | $37.68 | 2022-2025 | |
| Adc Therapeutics America, INC. | $33.95 | 2022-2023 | |
| Beigene USA, INC. | $30.90 | 2023-2024 | Brukinsa |
| Apellis Pharmaceuticals, INC. | $30.29 | 2024 | Empaveli |
| Organon LLC | $28.89 | 2023 | Ontruzant |
| Syndax Pharmaceuticals, INC. | $27.37 | 2025 | |
| Geron Corporation | $26.87 | 2025 | Rytelo |
| Pharmaessentia USA Corporation | $26.26 | 2025 | Besremi |
| Immunocore Limited | $26.16 | 2024 | Kimmtrak |
| Immunogen, INC. | $26.07 | 2023 | Elahere |
| Deciphera Pharmaceuticals INC. | $24.68 | 2024 | Qinlock |
| Gilead Sciences, INC. | $24.25 | 2023 | |
| Caris Mpi, INC. | $23.74 | 2025 | Mi Cancer Seek |
| Agios Pharmaceuticals, INC. | $22.75 | 2024 | Pyrukynd |
| Bayer Healthcare Pharmaceuticals INC. | $20.61 | 2024 | |
| Genzyme Corporation | $20.36 | 2023 | |
| Genmab U.S., INC. | $19.52 | 2023 | Epkinly |
| Emd Serono, INC. | $18.62 | 2022 | |
| Helsinn Therapeutics (U.S.), INC. | $17.50 | 2022 | |
| Myriad Genetic Laboratories, INC. | $13.51 | 2023 | Myrisk |
| Boehringer Ingelheim Pharmaceuticals, INC. | $11.65 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charis Durham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.